{"nctId":"NCT01261793","briefTitle":"Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)","startDateStruct":{"date":"2010-12"},"conditions":["Systemic Lupus Erythematosus"],"count":791,"armGroups":[{"label":"Placebo (Weekly infusion)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Epratuzumab 600 mg per week","type":"EXPERIMENTAL","interventionNames":["Drug: Epratuzumab"]},{"label":"Epratuzumab 1200 mg every other week","type":"EXPERIMENTAL","interventionNames":["Drug: Placebo","Drug: Epratuzumab"]}],"interventions":[{"name":"Placebo","otherNames":[]},{"name":"Epratuzumab","otherNames":[]},{"name":"Epratuzumab","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Positive antinuclear antibodies (ANA) at Screening (Visit 1)\n* Current clinical diagnosis of Systemic Lupus Erythematosus (SLE) by American College of Rheumatology (ACR) criteria such that at least 4 of the 11 criteria are met\n* Active moderate to severe SLE activity as demonstrated by the British Isles Lupus Assessment Group Index (BILAG)\n* Active moderate to severe SLE disease as demonstrated by SLE disease activity index (SLEDAI) total score\n* On stable SLE treatment regimen, including mandatory corticosteroids and immunosuppressants or antimalarials\n\nExclusion Criteria:\n\n* Subjects who are breastfeeding, pregnant, or plan to become pregnant\n* Subjects with active, severe SLE disease activity which involves the renal system\n* Subjects with active, severe, neuropsychiatric SLE, defined as any neuropsychiatric element scoring BILAG level A disease.\n* Subjects with the evidence of an immunosuppressive state\n* Subjects who, in the opinion of the investigator, are at a particularly high risk of significant infection\n* History of malignant cancer, except the following treated cancers: cervical carcinoma in situ, basal cell carcinoma, or dermatological squamous cell carcinoma.\n* Subjects receiving any live vaccination within the 8 weeks prior to screening (Visit 1).\n* Subjects with history of infections, including but not limited to concurrent acute or chronic viral hepatitis B or C\n* Subjects with substance abuse or dependence or other relevant concurrent medical condition\n* Subjects with history of thromboembolic events within 1 year of screening Visit.\n* Subjects with significant hematologic abnormalities\n* Subject has received treatment with other anti- B cell antibodies within 12 months prior to screening (visit 1)\n* Subject use of oral anticoagulant (not including) nonsteroidal anti-inflammatory drugs (NSAIDs) within 12 weeks prior to screening (Visit 1)\n* Subject has previously participated in this study or has previously received epratuzumab treatment.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Percent of Subjects Meeting Treatment Response Criteria at Week 48 According to a Combined Response Index","description":"Percentages are based on the number of subjects in the relevant treatment group within the Full Analysis Set (FAS). The combined response index incorporated criteria for achievement of responder status from the: British Isles Lupus Assessment Group Index (BILAG-2004)- improvement from study entry or no worsening in other organ systems, Systemic Lupus Erythematosus Disease Activity Index (SLEDAI; Version 2000, also known as SLEDAI-2K) - no worsening compared to study entry, physician's global assessment of disease activity(PGA)- no worsening compared to study entry, and concomitant medications- no changes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.5","spread":null},{"groupId":"OG001","value":"34.1","spread":null},{"groupId":"OG002","value":"35.2","spread":null}]}]}]},{"type":"SECONDARY","title":"The Percent of Subjects Meeting Treatment Response Criteria at Week 24 According to a Combined Response Index","description":"Percentages are based on the number of subjects in the relevant treatment group within the Full Analysis Set (FAS). The combined response index incorporated criteria for achievement of responder status from the: British Isles Lupus Assessment Group Index (BILAG-2004)- improvement from study entry or no worsening in other organ systems, Systemic Lupus Erythematosus Disease Activity Index (SLEDAI; Version 2000, also known as SLEDAI-2K) - no worsening compared to study entry, physician's global assessment of disease activity(PGA)- no worsening compared to study entry, and concomitant medications- no changes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.3","spread":null},{"groupId":"OG001","value":"33.0","spread":null},{"groupId":"OG002","value":"43.6","spread":null}]}]}]},{"type":"SECONDARY","title":"The Percent of Subjects Meeting Treatment Response Criteria at Week 12 According to a Combined Response Index","description":"Percentages are based on the number of subjects in the relevant treatment group within the Full Analysis Set (FAS). The combined response index incorporated criteria for achievement of responder status from the: British Isles Lupus Assessment Group Index (BILAG-2004)- improvement from study entry or no worsening in other organ systems, Systemic Lupus Erythematosus Disease Activity Index (SLEDAI; Version 2000, also known as SLEDAI-2K) - no worsening compared to study entry, physician's global assessment of disease activity(PGA)- no worsening compared to study entry, and concomitant medications- no changes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.0","spread":null},{"groupId":"OG001","value":"32.2","spread":null},{"groupId":"OG002","value":"40.9","spread":null}]}]}]},{"type":"SECONDARY","title":"The Percent of Subjects Meeting Treatment Response Criteria at Week 36 According to a Combined Response Index","description":"Percentages are based on the number of subjects in the relevant treatment group within the Full Analysis Set (FAS). The combined response index incorporated criteria for achievement of responder status from the: British Isles Lupus Assessment Group Index (BILAG-2004)- improvement from study entry or no worsening in other organ systems, Systemic Lupus Erythematosus Disease Activity Index (SLEDAI; Version 2000, also known as SLEDAI-2K) - no worsening compared to study entry, physician's global assessment of disease activity(PGA)- no worsening compared to study entry, and concomitant medications- no changes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.7","spread":null},{"groupId":"OG001","value":"33.0","spread":null},{"groupId":"OG002","value":"36.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Daily Corticosteroid Dose at Week 24","description":"Participants were grouped into 4 categories: Dose decreased by \\>50%, Dose decreased \\>0% to ≤50%, No change in dose and Dose increased or missing data.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","spread":"0"},{"groupId":"OG001","value":"10.0","spread":"0"},{"groupId":"OG002","value":"8.7","spread":"0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.9","spread":"0"},{"groupId":"OG001","value":"18.0","spread":"0"},{"groupId":"OG002","value":"18.2","spread":"0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.3","spread":"0"},{"groupId":"OG001","value":"46.7","spread":"0"},{"groupId":"OG002","value":"52.7","spread":"0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.2","spread":"0"},{"groupId":"OG001","value":"25.3","spread":"0"},{"groupId":"OG002","value":"20.5","spread":"0"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Daily Corticosteroid Dose at Week 48","description":"Participants were grouped into 4 categories: Dose decreased by \\>50%, Dose decreased \\>0% to ≤50%, No change in dose and Dose increased or missing data.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.5","spread":"0"},{"groupId":"OG001","value":"13.8","spread":"0"},{"groupId":"OG002","value":"14.8","spread":"0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.9","spread":"0"},{"groupId":"OG001","value":"13.4","spread":"0"},{"groupId":"OG002","value":"15.9","spread":"0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.7","spread":"0"},{"groupId":"OG001","value":"35.6","spread":"0"},{"groupId":"OG002","value":"36.7","spread":"0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.9","spread":"0"},{"groupId":"OG001","value":"37.2","spread":"0"},{"groupId":"OG002","value":"32.6","spread":"0"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":45,"n":263},"commonTop":["Urinary tract infection","Upper respiratory tract infection","Headache","Nausea","Nasopharyngitis"]}}}